KLTO
NASDAQKlotho Neurosciences Inc.
News25/Ratings0
News · 26 weeks150%
2026-03-012026-08-23
Mix090d
No activity.
Latest news
25 items- PRWhy a $35 Million Greenland Rare Earth Deal Just Put One Small-Cap on Every Investor's RadarIssued on behalf of Greenland Mines Ltd.A Toronto-listed industry leader is handing the keys to one of Greenland's most strategically valuable rare earth projects to a new Nasdaq-listed developer — and staying on as a partner.NEW YORK, May 21, 2026 /CNW/ -- USA NEWS GROUP News Commentary — The rare earth sector just got a fresh jolt of momentum. Rare earth elements — the 17 metals that power EV motors, wind turbines, fighter jets, robots, and just about every advanced electronic device — have become one of the most fought-over commodities on the planet. According to S&P Global, the supply of rare earths remains one of the least diversified among all critical minerals, with China still contro
- SECKlotho Neurosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Greenland Mines Ltd (0001907223) (Filer)
- SECKlotho Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Greenland Mines Ltd (0001907223) (Filer)
- PRKlotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRMLCompany to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The Company will hol
- SECKlotho Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)
- PRKlotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 9, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open on Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The rebranding and ti
- INSIDERChief Financial Officer Leblanc Jeff was granted 2,500,000 shares, increasing direct ownership by 272% to 3,420,342 units (SEC Form 4)4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
- INSIDERDirector El-Dada Riad Hussein was granted 350,000 shares (SEC Form 4)4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
- INSIDERDirector Zentman Samuel M was granted 350,000 shares, increasing direct ownership by 48% to 1,086,440 units (SEC Form 4)4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
- INSIDERDirector Hirschman Shalom was granted 350,000 shares, increasing direct ownership by 63% to 908,873 units (SEC Form 4)4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
- INSIDERDirector Mcgarity Jon was granted 350,000 shares, increasing direct ownership by 571% to 411,277 units (SEC Form 4)4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
- INSIDERChief Executive Officer Sinkule Joseph was granted 2,500,000 shares, increasing direct ownership by 65% to 6,346,700 units (SEC Form 4)4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
- SECKlotho Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)
- PRKLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDORTransaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland MinesCHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum
- SECKlotho Neurosciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)
- PRKlotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)The Company enlists industry veteran Dr. Bret Barnes to oversee the development of new diagnostic offeringsNEW YORK, Feb. 24, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the Company) announces the development of two genomics-based diagnostic tests that will be utilized in Klotho's clinical trials and to be provided as a service in the field of longevity and the understanding of the relationships between biological age and chronologic age. One genomics test being developed is a quantitative DNA methylation assay that determines the extent of DNA methylation of
- SECSEC Form 424B3 filed by Klotho Neurosciences Inc.424B3 - Klotho Neurosciences, Inc. (0001907223) (Filer)
- PRKlotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene SequenceNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the Company) announces the acceptance of 18 claims within a patent application filed in Australia for composition and use of human secreted Klotho protein ("s-KL") isoform of the human gene sequence. The Australian government entity IP Australia has notified the Company and the licensor of the technology, Universitat Autonoma de Barcelona, that these claims are to be granted. The 18 claims cover the use of a human muscle-cell specific promoter operatively linked to a nucleic acid gene sequence encoding human the human s-KL protein for treating motor impairment. The claims also cover the use of neuro
- SECKlotho Neurosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)
- SECSEC Form DEFR14A filed by Klotho Neurosciences Inc.DEFR14A - Klotho Neurosciences, Inc. (0001907223) (Filer)
- SECSEC Form DEF 14A filed by Klotho Neurosciences Inc.DEF 14A - Klotho Neurosciences, Inc. (0001907223) (Filer)
- SECSEC Form PRE 14A filed by Klotho Neurosciences Inc.PRE 14A - Klotho Neurosciences, Inc. (0001907223) (Filer)
- PRKlotho Neurosciences to Present at the Biotech Showcase 2026NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO, ", Klotho", , or ", the Company", )), a U.S.-based biogenetics company, announces that CEO Dr. Joseph Sinkule will be presenting at the 2026 Biotech Showcase in San Francisco on January 13, 2026 at 11:30AM PT. The Biotech Showcase is to be held January 12-14, 2026 at the Hilton San Francisco Union Square. At the event, the Company will be available for one-on-one meetings with investors and potential partners. To request a meeting, please contact ir@klothoneurosciences.com. About Klotho Neuroscien
- SECSEC Form EFFECT filed by Klotho Neurosciences Inc.EFFECT - Klotho Neurosciences, Inc. (0001907223) (Filer)
- INSIDERSEC Form 4 filed by Director Mcgarity Jon4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)
KLTO FAQ
5 questionsWhere does KLTO stock trade?
Klotho Neurosciences Inc. (KLTO) is listed on NASDAQ.What sector and industry is KLTO in?
Klotho Neurosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Klotho Neurosciences Inc. go public?
Klotho Neurosciences Inc. (KLTO) completed its IPO in 2022.What companies are similar to KLTO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare KLTO side-by-side with any of them on Quantisnow.How can I track KLTO on Quantisnow?
Quantisnow aggregates Klotho Neurosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KLTO to receive live email and push alerts on every new disclosure.